Investigational drug · Phase 3
Anaprazole
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Reflux Esophagitis (RE).
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 29, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
13
Any phase or sponsor naming "Anaprazole"
First trial start
2025
Jul 30, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Anaprazole", any sponsor or status.
Conditions studied
As listed on its trial records.
- Reflux Esophagitis (RE)
Approved drugs for the same conditions: Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "Anaprazole" as an intervention, largest first.
- The Clinical Trail to Evaluate the Efficacy and Safety of Anaprazole Sodium Enteric-coated Tablets Combined With Bismuth-containing Quadruple Therapy in Eradicating Helicobacter PyloriPivotal-lookingNot yet recruiting
Xuanzhu Biopharmaceutical Co., Ltd.Industry
NCT07606833 · 556 participants (planned) · Start Jun 10, 2026 · Primary completion Feb 19, 2027
Drug: Anaprazole Sodium enteric-coated tablet; Esomeprazole magnesium enteric-coated tablets · For: HELICOBACTER PYLORI INFECTIONS
Sites: Shenzhen, China
- A Clinical Trial of Anaprazole for Treating Reflux Esophagitis.Pivotal-lookingRecruiting
Xuanzhu Biopharmaceutical Co., Ltd.Industry
NCT07010107 · 500 participants (planned) · Start Jul 30, 2025 · Primary completion Apr 2026
Drug: Anaprazole + Rabeprazole placebo; Rabeprazole + Anaprazole placebo · For: Reflux Esophagitis (RE)
Sites: Shanghai, China
- A Phase 3 Randomised Controlled Trial to Evaluate Efficacy and Safety of Anaprazole in Patients With Duodenal Ulcers.Pivotal-lookingStatus unknown
Sihuan Pharmaceutical Holdings Group Ltd.Industry
NCT04215653 · 448 participants (planned) · Start Jan 20, 2020 · Primary completion Feb 15, 2021
Drug: Anaprazole Sodium; Rabeprazole and 2 more · For: Duodenal Ulcer,DU
- A Study of Anaprazole Sodium Enteric-coated Tablets in the Treatment of Reflux EsophagitisPivotal-lookingStatus unknown
Xuanzhu Biopharmaceutical Co., Ltd.Industry
NCT05604261 · 156 participants (planned) · Start Dec 2022 · Primary completion Jul 2023
Drug: Anaprazole sodium 40 mg; Anaprazole sodium 60 mg and 1 more · For: Reflux Esophagitis; Gastroesophageal Reflux; Esophagitis and 4 more
Sites: Shanghai, China
- A Phase 2 Randomised Controlled Trial to Evaluate Efficacy and Safety of Anaprazole in Patients With Duodenal Ulcers.Pivotal-lookingCompleted
Sihuan Pharmaceutical Holdings Group Ltd.Industry
NCT04503629 · 150 participants · Start Oct 9, 2018 · Primary completion May 17, 2019
Drug: Anaprazole Sodium; Anaprazole Sodium and 1 more · For: Duodenal Ulcer,DU
Sites: Nanchang, China
Sihuan Pharmaceutical Holdings Group Ltd.Industry
NCT04467060 · 74 participants · Start Aug 14, 2014 · Primary completion Jun 25, 2015
Drug: Anaprazole Sodium; Placebo · For: Healthy Male Volunteers
- A Study of the Pharmacokinetics and Safety of Anaprazole Sodium in Special PopulationsNot yet recruiting
Xuanzhu Biopharmaceutical Co., Ltd.Industry
NCT07345689 · 60 participants (planned) · Start Jan 30, 2026 · Primary completion Oct 30, 2026
Drug: Anaprazole Sodium enteric-coated tablet · For: Hepatic Insufficiency; Renal Insufficiency; Elderly
Sites: Changchun, China
- A Multiple Ascending High Dose Pharmacology Study of Anaprazole in Healthy Chinese SubjectsCompleted
Sihuan Pharmaceutical Holdings Group Ltd.Industry
NCT04471922 · 45 participants · Start Mar 21, 2019 · Primary completion Mar 28, 2019
Drug: Anaprazole Sodium enteric-coated tablet; Placebo and 1 more · For: Healthy Volunteers
Sites: Beijing, China
Sihuan Pharmaceutical Holdings Group Ltd.Industry
NCT04466748 · 36 participants · Start Sep 8, 2015 · Primary completion Dec 29, 2015
Drug: Anaprazole Sodium enteric-coated tablet; Placebo · For: Healthy Volunteers
- Pharmacokinetic Interactions of Quadruple Therapy With Anaprazole/Amoxicilin/Clarithromycin/BismuthStatus unknown
Sihuan Pharmaceutical Holdings Group Ltd.Industry
NCT04444011 · 32 participants (planned) · Start Jul 1, 2020 · Primary completion Sep 30, 2020
Drug: Anaprazole Sodium; Amoxicillin and 2 more · For: Healthy Male Volunteers
Newest research
PubMed records naming it or its code names, newest first.
- Anaprazole-based versus rabeprazole-based quadruple therapy for Helicobacter pylori eradication: a prospective, multicenter, randomized controlled trial.
Wang X, Wang H, Wang Y, et al. · Front Cell Infect Microbiol 2026
- Absorption, Metabolism, and Excretion of [14C]-Labeled Anaprazole: A New Proton Pump Inhibitor, After a Single Oral Administration in Healthy Chinese Male Subjects.
Xie L, Xu Y, Liu W, et al. · Clin Pharmacol Drug Dev 2024
- Integrated models of population pharmacokinetics and exposure response to optimize dosage regimen for anaprazole sodium in duodenal ulcer.
Zhang L, Song L, Cui C, et al. · Eur J Pharm Sci 2024
- Safety, Tolerability, and Pharmacokinetics of Anaprazole, a Novel Proton Pump Inhibitor, in Healthy Chinese Subjects.
Wang F, Niu X, Liu F, et al. · Clin Pharmacol Drug Dev 2024
- Cost-effectiveness analysis of Anaprazole versus Ilaprazole for the treatment of duodenal ulcers in China.
Ni H, Shi J, Hu M, et al. · Front Pharmacol 2024
- Physiologically based pharmacokinetic modeling to assess the drug-drug interactions of anaprazole with clarithromycin and amoxicillin in patients undergoing eradication therapy of H. pylori infection.
Liang N, Zhou S, Li T, et al. · Eur J Pharm Sci 2023
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.